期刊
PROTEOMICS
卷 13, 期 8, 页码 1314-1324出版社
WILEY
DOI: 10.1002/pmic.201200437
关键词
Alzheimer's disease; Animal proteomics; LC-MS; MS; Huperzine A; p53
资金
- Chinese Academy of Sciences
- E-institutes of Shanghai Municipal Education Commission [E03008]
- Shanghai Science and Technology Development Fund [12QA1404000]
- Ministry of Science and Technology of China [2011CB510004]
- National Natural Science Foundation of China [81173034, 81072646]
- Natural Science Foundation of Shanghai [12ZR1436400]
Alzheimer's disease is a worldwide metabolic disease and an economically costly disease to society, so more medicines need to be developed to treat this disease. Huperzine A, a novel lycopodium alkaloid isolated from traditional Chinese medicine Huperzia serrata (Qian Ceng Ta), has been shown to possess multiple neuroprotective effects for Alzheimer's disease, but the precise pharmacological mechanism of huperzine A is unclear and needs to be further investigated. In this study, proteins from untreated N2a cells (Con group), cells preincubated with huperzine A followed by A (142) oligomers treatment (HupA group) and cells treated with A (142) oligomers (A group) with five biological replicates in each cohort, were processed in a centrifugal proteomic reactor and quantified by label-free quantitation. A total of 2860 proteins were quantified with high confidence, and 198 proteins were significantly changed (with p-value < 0.05) between HupA and A cohorts. The pathway and direct proteinprotein interaction network analysis showed that huperzine A protects N2a cells against A oligomer-induced cell death by downregulation of cellular tumor antigen p53 (Trp53) expression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据